One causal model of preeclampsia (PE) postulates that placental hypoxia alters the production of angiogenic growth effectors (AGEs), causing an imbalance leading to maternal endothelial cell dysfunction. We tested this model using the natural experiment of high-altitude (HA) residence. We hypothesized that in HA pregnancies 1) circulating soluble fms-like tyrosine kinase 1 (sFlt-1) is increased and placental growth factor (PlGF) decreased, and 2) AGE concentrations correlate with measures of hypoxia. A cross-sectional study of healthy pregnancies at low altitude (LA) (400 m) versus HA (3600 m) compared normal (n ¼ 80 at HA, n ¼ 90 at LA) and PE pregnancies (n ¼ 20 PE at HA, n ¼ 19 PE at LA). Blood was collected using standard serum separation and, in parallel, by a method designed to inhibit platelet activation. AGEs were measured by enzyme-linked immunosorbent assays. AGEs did not differ between altitudes in normal or PE pregnancies. AGE concentrations were unrelated to measures of maternal or fetal hypoxia. PlGF was lower and sFlt-1 higher in PE, but overlapped considerably with the range observed in normal samples. PlGF correlated with placental mass in both normal and PE pregnancies. The contribution of peripheral cells to the values measured for AGEs was similar at LA and HA, but was greater in PE than in normotensive women. Hypoxia, across a wide physiological range in pregnancy, does not alter levels of circulating AGEs in otherwise normal pregnancies. Peripheral cell release of AGEs with the hemostasis characteristic of standard blood collection is highly variable and contributes to a doubling of the amount of sFlt-1 measured in PE as compared to normal pregnancies.
INTRODUCTION
Attention has focused on circulating angiogenic growth effectors and their binding proteins (AGEs) in pregnant women as being causally related to the human-specific pregnancy syndrome known as preeclampsia (PE) [1] [2] [3] [4] . AGEs implicated in PE are free vascular endothelial growth factor (VEGF), free placental growth factor (PlGF), and their binding protein, soluble fms-like tyrosine kinase 1 (sFlt-1). Endoglin [5] and, more recently, soluble endoglin [6] as well as splice variants of sFlt-1 [7, 8] have also emerged as potential biomarkers and mediators of endothelial cell dysfunction. Soluble Flt-1 can limit growth factor-stimulated transactivation by sequestering VEGF and PlGF or by forming inactive heterodimers with the transmembrane receptors Flk and Flt-1 [9] . In PE, the causal argument is that binding of free VEGF and PlGF by excess sFlt-1 inhibits their beneficial actions on the vascular endothelium, permitting the systemic endothelial cell damage that is thought to precipitate PE symptoms [10] . This is reflected in the circulation of some preeclamptic women by high levels of sFlt-1 and low levels of PlGF and free VEGF. Why sFlt-1 is elevated in preeclamptic pregnancy is not completely understood. However oxygen tension is a major regulator of the expression of AGEs in the placenta [11] [12] [13] [14] [15] [16] [17] . Specifically, sFlt-1 increases with lowered oxygen tension, and PlGF and VEGF decrease with higher oxygen tension [18] [19] [20] . All three AGEs are subject to regulation by the nuclear transcription factor hypoxia-inducible factor-1 (HIF-1), which is elevated in PE [16, 21] . This has led to the hypothesis that placental hypoxia causes excess production of sFlt-1 and thus decreases maternal circulating free PlGF and free VEGF in preeclamptic pregnancies.
We tested this hypothesis using the natural experiment afforded by human residence at high altitude (HA), in which maternal arterial PO 2 is diminished by ;30% and fetal PO 2 by ;10%, and there is clear evidence of maternal, placental, and fetal hypoxia [16, [22] [23] [24] . The incidence of PE is increased by 2-to 4-fold at HA, supporting the idea that hypoxia is contributory [25, 26] . Many of the normal physiological changes of pregnancy are altered at HA so that values are intermediate between normal pregnancy at sea level and PE [27] . Levels of HIF-1alpha are doubled in HA placentae, similar to what is reported in PE [21, 22] . Given that we have shown that the mother, fetus, and placenta are hypoxic relative to sea-level controls, we would expect higher levels of hypoxia-stimulated AGEs and lower levels of those unresponsive to hypoxia.
We tested two specific hypotheses. First, we predicted that we would find increased sFlt-1 and decreased PlGF in HA pregnancy. Second, we hypothesized that AGE levels would correlate with maternal and/or fetal oxygenation. We did not measure free VEGF because we have shown that detectable levels are an artifact of blood collection technique in both the maternal and fetal circulation. In the same study, we demonstrated that 83%, 29%, and 20% of maternal circulating levels of VEGF, PlGF, and sFlt-1, respectively, were attributable to peripheral cell release/secretion and highly variable from individual to individual [28] . In the fetal circulation, peripheral cell contribution to AGEs using standard blood collection methods was 98% of free VEGF and 59% of sFlt-1, with a significant increase in the number of samples with nondetectable levels [28] . Therefore, in this study we also tested to what extent altered concentrations in AGEs, if present, may be due to secretion/release by other cell types within the circulation. AGEs are known to be produced/stored/bound/ released by peripheral cells in the circulation, and it is possible that chronically lowered maternal PO 2 may alter these processes [29] [30] [31] .
MATERIALS AND METHODS

Research Design, Subjects, and Sites
The present study was part of a larger, cross-sectional study evaluating the effects of altitude and genetic ancestry on uterine and umbilical blood flows, O 2 delivery/consumption, placental function, and pregnancy outcome [23, 24] . Genetic ancestry was assessed using 133 single nucleotide polymorphisms that permit individual estimates of biogeographic ancestry, for example, a participant might be 80% Native American, 12% European, 4% sub-Saharan African, and 4% East Asian. For the variables we report here, biogeographic ancestry had no impact. Therefore, we compared all the women at low altitude (LA) (400 m, n ¼ 90) with all HA pregnancies (3600 m, n ¼ 80). An additional 39 pregnancies complicated by PE, 20 at HA and 19 at LA, were compared with their respective altitude controls. All the participants gave written, informed consent as approved by the Bolivian National Bioethics Committee, the local Institutional Review Boards, and our U.S. Institutional Review Board. Inclusion criteria were good health (absence of chronic conditions that predispose to PE, e.g., hypertension, renal disease, or obesity), conception, gestation, and delivery at the altitude of study. Women were excluded for drug, alcohol, or tobacco use, or a positive oral glucose tolerance test. All the women remained at their altitude of residence for their entire pregnancy.
Preeclampsia was defined using National Institutes of Health consensus guidelines [32] . Hypertension was defined as !140 mmHg systolic or !90 mmHg diastolic on two or more occasions in previously normotensive pregnancies in the third trimester. Proteinuria was present where readings of !2þ on dipstick and/or !0.3 g protein in a 24-h urine collection were present in the absence of urinary tract infection. The sample size for PE does not permit division into the most informative hierarchy, that is, early onset PE and lateonset PE with versus without intrauterine growth restriction. The data are therefore divided into early onset of symptoms (,34 wk) and delivery at ,35.9 wk gestational age, and late onset cases in which symptoms and delivery occurred later than !36 wk.
Blood Collection and Measures of Oxygenation
One to ten days prior to elective cesarean delivery (mean 6 SEM, 3 6 1 days), mothers completed a health screen and medical history. An arterialized blood sample (warmed hand vein) was drawn for measurement of blood gases and oxygen content as previously described [23] . Upon admission for cesarean delivery, a 15 ml maternal venous blood sample was distributed into serum separator vacutainers at room temperature and into ice-cold vacutainers containing sodium citrate, theophylline, adenosine, and dipyridamole (CTAD) as previously described [28] . CTAD is added to prevent platelet activation and release of platelet-derived factors into the plasma, but CTAD likely prevents activation of other peripheral cells as well. No supplemental oxygen was used prior to maternal blood sampling. Blood samples were allowed to clot for 30 min at room temperature; serum was then separated by centrifugation (2000 3 g for 10 min). The CTAD tubes were prechilled, placed on ice before and after blood collection, and immediately centrifuged for 10 min at 2000 3 g at 48C to collect plasma. Samples were flash frozen in liquid nitrogen and stored at À808C until analysis. None of the samples tested for this report had been previously thawed. We chose the CTAD method based on reports indicating that failure to control for clotting time invalidates the use of VEGF as an indicator of disease states [33] [34] [35] . The other AGEs have not, to our knowledge, been tested with this method before our recent examination of the effects of hemostasis on AGE concentrations in maternal and fetal cord blood in normal LA pregnancies [28] .
Assays
All the enzyme-linked immunosorbent assay kits were purchased from or donated by R&D Systems (sVEGF R1/Flt-1 [DVR-100] and free PlGF [DPG00]; Minneapolis, MN). Curve-fitting (linear or polynomial) was used for generation of standard curves and subsequent calculation of the unknown (sample) values. Not all the assays could be done on all the subjects because never-thawed samples were not available for some women. Sample sizes for each assay are given in the figure legends.
Validation Studies
Validation studies have been reported in detail elsewhere [28] . Briefly, to ensure that the CTAD reagent was not interfering with the enzyme-linked immunosorbent assay, the linearity of the standard curves with versus without CTAD was evaluated. The curves were overlapping and linear with an r 2 ! 0.98. In addition, to ensure that a CTAD/plasma reaction would not alter the results, we examined a heparin-treated plasma sample (no CTAD) with a known concentration of the AGE of interest. When diluted for analysis, one aliquot was treated with standard diluent and the other with diluent plus 15 ll CTAD reagent. The values obtained did not differ between the CTAD treated versus untreated samples. For each assay, spike and recovery experiments and serial dilutions were used to test the dynamic range of the assay, to determine the extent to which experimental samples required dilution to fall within the standard curves, and to assure full recovery at high and low ends of the range of values. Linearity tests in the PlGF assay yielded an r 2 of 0.96 and of 0.98 for sFlt-1. The intraassay coefficient of variation (CV 6 SD) was calculated for the duplicate samples within each plate and averaged across all the plates. Interassay variation was calculated using the pooled samples mentioned above, in triplicate on every plate. For PlGF, the intraassay CV was 3.6% 6 8.9%, and for sFlt-1, the CV was 3.2% 6 6.1%. The interassay CV was 9% 6 8% for PlGF and 15% 6 10% for sFlt-1.
PlGF
The detection limit is reported as !7.0 pg/ml. A 4-fold dilution was determined as optimal and used for all the samples. All the samples had detectable levels of PlGF, and none were ,7 pg/ml.
Soluble Flt-1
The reported detection limits ranged from 1.5-13.3 pg/ml, with a mean of 3.5 pg/ml. We measured matched serum and CTAD plasma samples from the normal and preeclamptic mothers. A 20-fold dilution was required in the maternal samples. All the serum samples had detectable levels of sFlt-1. In the maternal preeclamptic samples, 20-to 100-fold dilutions were required to obtain values within the range of the standards.
Statistical Analysis
None of the AGEs passed the D'Agostino and Pearson normality test. Thus, for the matched serum versus CTAD samples, a Wilcoxon signed rank test was used to determine whether the conditions of blood collection influenced the results. The Mann-Whitney U-test was used to compare between altitudes. Data are presented as box and whiskers or scatter plots. In box plots, the median is indicated by the bar, the 25th and 75th centiles by the box, and the maximum and minimum by whiskers. In the text and legends, brackets [ ] indicate the interquartile range. Maternal and fetal demographic and clinical data are reported as the mean 6 SEM. Comparison between the normal and preeclamptic subject groups was analyzed by the Kruskal-Wallis test followed by Dunn multiple comparison test. Categorical data was analyzed by chi square. Regression analyses were used to compare the relationship between AGE concentrations, gestational age, birth or placental weight, and maternal or fetal measures of oxygenation. Values were considered significant where P was 0.01; the P value was reduced (Bonferroni correction) because the AGEs in normal women were tested three times, by altitude, compared with PE and by serum versus CTAD blood collection procedures.
ZAMUDIO ET AL. Table 1 shows the characteristics of the healthy women and their neonates. Mothers were generally similar in their demographic characteristics, but birth weight was lower in the HA pregnancies despite similarity in gestational age. Adjustment for variation in maternal height, body mass index, weight gain with pregnancy, and parity and for neonatal gestational age and fetal sex did not appreciably change the birth weights (Table 1 ). In short, demographic factors do not explain the altitude-associated decrement in birth weight, which is accompanied by reduced body length and abdominal circumference but preserved head circumference. Mothers at 3600 m relative to 400 m had lower PO 2 and blood oxygen saturation (SaO 2 , P , 0.0001). Arterial PO 2 was 54 6 1 mmHg (range 46-72) whilst at 400 m, PaO 2 was 92 6 1 mmHg (range 84-115). Arterialized blood is not as reliable as data obtained by direct arterial puncture for measurement of PO 2 ; saturation (SaO 2 ) is more reliable and ranged from 94% to 99% at LA and from 85% to 94% at HA. The fetuses also had lower umbilical venous PO 2 (27 6 1 mmHg at 3600 m, range, 15-41, vs. 31 6 1 mmHg at 400 m, range, 9-46, P , 0.01), but not SaO 2 [24] .
PlGF
PlGF concentrations were similar at 400 and 3600 m and were not decreased at HA as predicted (Fig. 1A) . The values obtained from CTAD samples also did not differ by altitude (Fig. 1B) . However CTAD treatment decreased PlGF by onethird relative to the paired serum samples (Fig. 1B) . The decrement ranged from 11% to 67% at LA and from 13% to 78% at HA. The initial, serum-derived values for PlGF were unrelated to the percent decrease with CTAD (r 2 ¼ 0.02, P ¼ 0.58 at LA; r 2 ¼ 0.00, P ¼ 0.94 at HA), that is, whether initial PlGF values were high or low did not appear to influence the change observed with CTAD. Values were unrelated to gestational age or birth weight. However at both altitudes, maternal circulating PlGF concentrations were positively correlated with placental weight (Fig. 1C, r 2 at each altitude ¼ 0.17, P , 0.001).
Soluble Flt-1
Concentrations of sFlt-1 did not differ between LA and HA ( Fig. 2A) . Collection of blood into CTAD reduced sFlt-1 concentrations in healthy pregnant women by 22% 6 3% and 23% 6 3% at 400 and 3600 m, respectively (Fig. 2B ). Values obtained with CTAD also did not differ between altitudes. The range of variation was large, from 0% to 69% decrease at LA and from 0% to 83% decrease at HA. One subject at LA and three at HA had a decline in sFlt-1 values with CTAD, but the difference was less than 7%. There was no correlation with gestational age or placental or birth weight. The initial, serumderived values for sFlt-1 were unrelated to the percent decrease with CTAD (r 2 ¼ 0.00, P ¼ 0.89 at LA; r 2 ¼ 0.01, P ¼ 0.72 at HA).
In summary, the results for these AGEs show that in both plasma and serum samples, none differ by altitude in healthy, normal pregnancies despite lowered maternal and fetal PO 2 . Moreover, the results from CTAD plasma samples show that a third of the circulating free PlGF and nearly a quarter of sFlt-1 in serum samples collected under standard clinical conditions are derived from other cells in the maternal circulation. The degree to which hemostasis alters these AGE concentrations is highly variable from individual to individual and unrelated to having either high or low values, precluding any form of standard correction for hemostatic effects.
Women with Preeclampsia
The characteristics of and clinical data pertinent to the mothers and infants in the preeclamptic samples are given in Table 2 . As would be expected, these subjects were younger, virtually all were primiparous, had lower gestational age at delivery, and had lower birth and placental weights than their normotensive counterparts. The median and interquartile ranges for PlGF and sFlt-1 are also given in Table 2 for the early and late-onset groups; however, because there was no significant difference between these groups and given the small sample size, the data were consolidated for the figures and statistical analyses. Maternal oxygen tension in preeclamptics was 93 6 3 mmHg (range: 80-114) at 400 m and 59 6 3 mmHg (range: 44-75) at 3600 m; similar to those obtained in 
Preeclampsia and PlGF
There were no altitude-associated differences in PlGF concentrations among the preeclamptic women, but preeclamptic women had lower PlGF concentrations than their normotensive counterparts (P , 0.001) regardless of altitude (Fig.  3A) . Early versus late onset PE did not differ in PlGF concentrations (Table 2 and Fig. 3B ). Collection into CTAD reduced the PlGF values in preeclamptics ( Fig. 3B ; P , 0.001) by 25% 6 5% at LA and by 32% 6 4% at HA ( Fig. 3B ; P , 0.001). As in the normotensive women, the reduction was quite variable, ranging from 0% to 52% at LA and from 13% to 71% at HA. The decrement was similar between altitudes and did not differ between normotensive and preeclamptic pregnancies. The correlation between PlGF and placental weight was significant at both altitudes in PE (Fig. 3C) . There was no relationship with gestational age or newborn weight.
Preeclampsia and sFlt-1
Soluble Flt-1 serum levels did not differ between preeclamptic groups at LA versus HA (Fig. 4A ), but were greater in PE than normotensive women at both altitudes. Collection into CTAD reduced sFlt-1 levels by 36% 6 5% at 400 m and 42% 6 5% at 3600 m (Fig. 4B) . As in the normotensive women, the reduction was quite variable, ranging from 0% to 65% at LA and from 8% to 74% at HA. While these values do not differ from each other, the CTAD-associated reduction in sFlt-1 is greater among preeclamptics than that observed in the normotensive women (41% for all PE vs. 23% for all normotensive, P , 0.0001). There was no difference in sFlt-1 levels in early versus late-onset preeclamptic women (Table 2 and Fig. 4, A and B) , nor did the CTAD-associated decrement in sFlt-1 vary by severity of disease. Soluble Flt-1 levels were not related to gestational age, birth, or placental weight. 
ZAMUDIO ET AL.
Associations Between Variables
We tested the hypothesis that variation in maternal and fetal oxygenation would be related to maternal circulating levels of AGEs. We conducted regression analyses of maternal PO 2 , arterial O 2 content, and erythropoietin levels, and of fetal umbilical venous and arterial PO 2 , O 2 content, and erythropoietin concentrations (x axis) with PlGF and sFlt-1 concentrations (y axis). These indicators of maternal and fetal oxygenation showed no relationship to the AGEs, with the r 2 values ranging from 0.00 to 0.06. This was true whether it was considered in relation to the entire sample or within each altitude. The hypothesis that variation in circulating angiogenic growth factors might be related to differences in maternal or fetal oxygenation was thus rejected.
DISCUSSION
The hypotheses tested were not supported. Free PlGF and the soluble binding protein, sFlt-1, did not differ in LA versus HA pregnancies. Surprisingly, given the significant differences in maternal PO 2 and SaO 2 , fetal PO 2 , and the levels of placental HIF-1alpha and its target genes at HA, multiple indicators of oxygenation were unrelated to circulating levels of AGEs. The extended physiological range of 46 to .100 mmHg arterial PO 2 in mothers and of 9-46 mmHg in fetuses was not associated with variation in circulating AGEs. Serum is a widely collected clinical sample. Based on parallel collection of standard serum samples versus immediately processed plasma samples with reagents designed to inhibit platelet activation, we have shown that one-third of PlGF and nearly a quarter of sFlt-1 was secreted/released into blood during hemostasis. Moreover, nearly twice as much sFlt-1 came from peripheral circulatory sources in preeclamptic versus normotensive pregnant women, perhaps accounting for many of the discrepancies in the literature regarding the association (or lack thereof) of sFlt-1 with PE. In serum samples, and possibly in other types of plasma samples, if blood is not processed immediately, this extra PlGF and sFlt-1 appears to be an artifact of blood collection technique. During hemostasis, these growth effectors are likely released by other cell types within the circulation, for example, platelets and granulocytes [29] and other peripheral blood mononuclear cells [30, 31] . Therefore, their alteration in pregnancy pathologies does not necessarily reflect changes in placental production.
Challenges to the interpretation of these results include 1) possible differences between the collection sites, 2) the combining of two different ethnic groups at each altitude, 3) assay variability, 4) additional splice variants of sFlt-1, and 5) the lack of gestational age-matched controls for the PE patients. Ambient temperature and barometric pressure were recorded as part of the blood gas measurement protocol. We tested the serum values against ambient room temperature and found no correlation, and nor was any relationship apparent when using cruder measures such as comparing values obtained during summer versus winter.
Women of Native American (Andean) ancestry suffer less altitude-associated growth restriction than European migrants. They are not, however, protected from the altitude-associated excess risk of PE [26] . We found no evidence to support ancestry-associated differences in the AGEs, but cannot rule out they may exist between other ethnic groups. In the only other report on Bolivians, altitude decreased sFlt-1 in both native and migrant women and was negatively associated with uterine artery diameter and birth weight in Europeans [36] . We were unable to replicate these findings. Soluble Flt-1 did not differ between ancestry groups or altitudes, and the correlation Late-onset PE (n ¼ 12)
Early-onset PE (n ¼ 10)
Late-onset PE (n ¼ 10)
Maternal Age (yr) 26 6 2 2 5 6 1 2 9 6 2 2 7 6 2 P , 0.005 Primiparous (n) 6/7 10/10 9/10 9/10 P , 0.0001 Height (cm) ANGIOGENIC GROWTH EFFECTORS IN HYPOXIC PREGNANCY coefficient (r 2 ) for uterine artery diameter and sFlt-1 was 0.05 and for birth weight was 0.08 to altitude among migrants. These differences, and the high variability of reported values for AGEs in the literature cast doubt on the utility of these measures for clinical diagnoses.
We are aware that additional splice variants of sFlt-1 have been discovered [37] and are produced by the hypoxic placental trophoblast [7, 38] and that it is unknown whether current assays measuring sFlt-1 can distinguish between these splice variants. Finally, the lack of age-matched controls for the PE patients is a weakness, but it was not possible to collect such samples in the absence of some other pathology. In summary, variability in, among other factors, the assays themselves, the testing conditions, blood collection protocols, and length of storage, if not accounted for, are all likely to contribute to heterogeneity in the results reported in the relevant literature.
Much of what we know about the interaction between the AGEs, vascular endothelium, and disease states is not consistent with the pattern argued as a causal contributor to PE. In theory, lower free VEGF should be beneficial because high levels of free VEGF in nonpregnant persons are associated with hypertension, glomerulosis, altered vascular reactivity, and vascular leak, all the hallmarks of PE [39] [40] [41] [42] [43] . Excess PlGF, like VEGF, is implicated in hypertension and vascular disease [44] . Stretch, shear stress, hypoxia, and proinflammatory stimuli will induce PlGF expression [45] [46] [47] [48] [49] . PlGF is known to stimulate monocyte production of proinflammatory cytokines [50] that are elevated in PE [51] . Hence, the evidence favors increased, not decreased, PlGF as a causal component of PE. Placental size was correlated with PlGF in both our normal and preeclamptic pregnancies. However the absence of excess PlGF in twin pregnancy argues against placental mass as a primary determinant. The rise in PlGF in the maternal 
FIG. 4. A)
Open squares and diamond symbols are early and late onset PE, respectively, at LA; filled squares and diamonds are early and late onset PE, respectively at HA. Soluble Flt-1 serum levels (ng/ml) were greater than in normotensive women at each altitude but did not differ in preeclamptic women at LA (median ¼ 43) [16, 97] versus HA (median ¼ 49; P ¼ 0.49) [27, 133] . B) Collection into CTAD reduced sFlt-1 levels by 36% 6 5% at 400 m and 42% 6 5% at 3600 m (P , 0.005). While these values do not differ from each other, the CTAD-associated reduction in sFlt-1 is significantly greater among preeclamptics than what was observed in the normotensive women (P , 0.0001).
ZAMUDIO ET AL. circulation in the early second trimester is exponential, correlates with Doppler indicators of placental perfusion, and likely reflects placental perfusion as well as increase in mass [52] . Alternatively, opening of the maternal intervillous space to blood flow at ;10-12 wk may induce PlGF due to shear stress or stretch [46, 47] , which is largely complete by 32 wk, thereafter removing the stretch stimulus, which may be why PlGF declines in the third trimester. In either case, hypoperfusion due to impaired development of the spiral arteries and/or failed growth of the placenta, common in severe PE, may account for the relatively lower levels of PlGF in preeclamptic pregnancy without necessarily having any impact on the maternal endothelium or on the development of symptoms. Again the question must be asked, what does a relative paucity of PlGF actually do to endothelial cell health in pregnancy?
Soluble Flt-1 is a splice variant of VEGF receptor 1. Production by the placenta was first reported in 1998 [53] ; reports on the elevation of sFlt-1 in PE and by hypoxia followed in 2000 [2, 18] . In normal pregnancy, but not PE, the rise in sFlt-1 correlates with the third trimester rise in blood pressure [54] . We found no association with mean arterial pressure in this study (r 2 values ranged from 0.00 to 0.04 within and between altitudes). Nonetheless, antihypertensive therapy reduces sFlt-1 in preeclamptics [55] . As with VEGF and PlGF, the damaging role claimed for elevated sFlt-1 in preeclamptic pregnancy is counterintuitive. Soluble Flt-1 is lower in hypertensive men and elevated by therapies designed to ameliorate cardiovascular risk. It is worth noting that PlGF values in PE overlap entirely with those of normotensive women, while sFlt-1 levels overlap in at least half the cases (Figs. 3 and 4) . The source of the excess sFlt-1 in PE has not been fully established. We show here, in theory, that excess placental production is not reflected in the maternal circulation with physiological hypoxia. Alternatively, if there is excess placental production in PE, not due to hypoxia, it may be bound by peripheral cells in the circulation and contribute to the higher values of sFlt-1 in preeclamptic women. Preeclampsia is associated with failure of plasma volume expansion, which may contribute to higher sFlt-1 levels resulting simply from hemoconcentration. However, if this was the case, we would expect to see elevated sFlt-1 at HA because plasma volume is lower in both the nonpregnant and pregnant state [56] . Cells other than platelets must be involved because HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome, characterized by thrombocytopenia, has AGE profiles similar to PE whereas idiopathic thrombocytopenia in pregnancy is associated with lower sFlt-1 and higher PlGF than normal pregnancy [57] . Altered levels of peripheral blood mononuclear cells, activation of platelets (which are normally reduced), and altered leucocyte populations in the maternal decidua have all been reported in PE [58] and may also contribute to variation in circulating concentrations of AGEs.
Our results support the accumulating evidence in the literature that the AGEs studied here play a correlative rather than causal role in PE. It is at least possible that elevated sFlt-1 is a protective response to excess free VEGF production by the hypoxic placenta. It is noteworthy that free VEGF decreases by an order of magnitude or more from the nonpregnant state and that, unlike in rodents, which are common models for PE, there is basically no free VEGF circulating in human pregnancy. A recent National Institutes of Health trial revealed that first trimester values of AGEs have little predictive value [59] even if supplemented with Doppler measures of resistance. Some groups have shown changes in the mean values of maternal circulating angiogenic growth factors several weeks prior to the onset of symptoms [4, 60, 61] , while others have not, or have found changes prior to symptom onset only in individuals at known high risk [62, 63] . Negative publication bias may have limited the numbers of reports in which no predictive value was shown. Others have shown that the values obtained have low sensitivity and specificity [64, 65] , and are unrelated to markers of endothelial cell dysfunction [66] , and that changes are due to an increase in blood pressure rather than the reverse [54] . The significant overlap between the values obtained in normotensive versus preeclamptic pregnancy reported here and elsewhere, combined with the variable change in the degree to which activation of peripheral cells contributes to the values measured, suggests that circulating values are unlikely to attain a sufficient degree of specificity and sensitivity for use as a reliable diagnostic test. Finally, our results argue against hypoxia as specifically, causally associated with changes in circulating angiogenic growth factors: lowered maternal or fetal PO 2 does not appear to cause change in tissue production and release into the circulation of the angiogenic growth factors tested here.
In summary, we have shown that multiple measures of maternal and fetal hypoxia are not related to circulating AGEs in human pregnancy. The hypothesis that placental hypoxia increases secretion of sFlt-1 into the maternal circulation is not supported by these data. Standard serum samples do not accurately reflect the actual levels of circulating AGEs in pregnant women. That the error is much greater for serum levels of sFlt-1 in pregnancies complicated by PE points to one possible explanation for discrepancies in the literature regarding the extent to which elevated sFlt-1 may or may not precede development of symptoms. This casts doubt on the theory that excess circulating sFlt-1 is causally associated with the development of symptoms. More fruitful research might focus on how cells in the peripheral circulation interact with the maternal endothelium and to what extent highly localized release of growth factors may influence endothelial cell function to protect against or exacerbate preeclamptic symptoms.
